COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral responses.
dc.contributor.author | Bonifacius, Agnes | |
dc.contributor.author | Tischer-Zimmermann, Sabine | |
dc.contributor.author | Dragon, Anna C | |
dc.contributor.author | Gussarow, Daniel | |
dc.contributor.author | Vogel, Alexander | |
dc.contributor.author | Krettek, Ulrike | |
dc.contributor.author | Gödecke, Nina | |
dc.contributor.author | Yilmaz, Mustafa | |
dc.contributor.author | Kraft, Anke R M | |
dc.contributor.author | Hoeper, Marius M | |
dc.contributor.author | Pink, Isabell | |
dc.contributor.author | Schmidt, Julius J | |
dc.contributor.author | Li, Yang | |
dc.contributor.author | Welte, Tobias | |
dc.contributor.author | Maecker-Kolhoff, Britta | |
dc.contributor.author | Martens, Jörg | |
dc.contributor.author | Berger, Marc Moritz | |
dc.contributor.author | Lobenwein, Corinna | |
dc.contributor.author | Stankov, Metodi V | |
dc.contributor.author | Cornberg, Markus | |
dc.contributor.author | David, Sascha | |
dc.contributor.author | Behrens, Georg M N | |
dc.contributor.author | Witzke, Oliver | |
dc.contributor.author | Blasczyk, Rainer | |
dc.contributor.author | Eiz-Vesper, Britta | |
dc.date.accessioned | 2021-02-26T16:19:45Z | |
dc.date.available | 2021-02-26T16:19:45Z | |
dc.identifier.citation | Immunity. 2021 Feb 9;54(2):340-354.e6. doi: 10.1016/j.immuni.2021.01.008. | en_US |
dc.identifier.pmid | 33567252 | |
dc.identifier.doi | 10.1016/j.immuni.2021.01.008 | |
dc.identifier.uri | http://hdl.handle.net/10033/622758 | |
dc.description.abstract | Cellular and humoral immunity to SARS-CoV-2 is critical to control primary infection and correlates with severity of disease. The role of SARS-CoV-2-specific T cell immunity, its relationship to antibodies, and pre-existing immunity against endemic coronaviruses (huCoV), which has been hypothesized to be protective, were investigated in 82 healthy donors (HDs), 204 recovered (RCs), and 92 active COVID-19 patients (ACs). ACs had high amounts of anti-SARS-CoV-2 nucleocapsid and spike IgG but lymphopenia and overall reduced antiviral T cell responses due to the inflammatory milieu, expression of inhibitory molecules (PD-1, Tim-3) as well as effector caspase-3, -7, and -8 activity in T cells. SARS-CoV-2-specific T cell immunity conferred by polyfunctional, mainly interferon-γ-secreting CD4+ T cells remained stable throughout convalescence, whereas humoral responses declined. Immune responses toward huCoV in RCs with mild disease and strong cellular SARS-CoV-2 T cell reactivity imply a protective role of pre-existing immunity against huCoV. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Elsevier (Cell Press) | en_US |
dc.relation.url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871825/ | en_US |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | COVID-19 | en_US |
dc.subject | SARS-CoV-2 | en_US |
dc.subject | antibody | en_US |
dc.subject | antiviral T cell immunity | en_US |
dc.subject | caspases | en_US |
dc.subject | cell death | en_US |
dc.subject | chemokine receptors | en_US |
dc.subject | convalescence | en_US |
dc.subject | endemic human coronavirus | en_US |
dc.subject | humoral immunity | en_US |
dc.title | COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral responses. | en_US |
dc.type | Article | en_US |
dc.identifier.eissn | 1097-4180 | |
dc.contributor.department | CiiM, Zentrum für individualisierte Infektionsmedizin, Feodor-Lynen-Str.7, 30625 Hannover. | en_US |
dc.identifier.journal | Immunity | en_US |
dc.identifier.pmcid | PMC7871825 | |
dc.source.volume | 54 | |
dc.source.issue | 2 | |
dc.source.beginpage | 340 | |
dc.source.endpage | 354.e6 | |
refterms.dateFOA | 2021-02-09T00:00:00Z | |
dc.source.journaltitle | Immunity | |
dc.source.country | United States |